Publications Office of the EU
EURL ECVAM recommendation on non-animal-derived antibodies
DisplayCustomHeader
MyPortal
português
BasketSummary
Visualizador de Conteúdo Web
Publication Detail Actions Portlet

Ferramentas

Publication Detail Actions Portlet
 Avaliação do utilizador
custom-survey-notification
Publication Detail Portlet

Publication detail

Home

EURL ECVAM recommendation on non-animal-derived antibodies

Metadados da publicação

Antibodies are binding molecules (affinity reagents) that have a high specificity for their unique target (antigen) and are crucial tools for research, diagnostics, therapeutics and regulatory procedures. Animals are still used for the generation of monoclonal and polyclonal antibodies as well as other types of affinity reagents despite the availability of technologies for their development and production that do not entail the use of animals. The EU Directive 2010/63/EU on the protection of animals used for scientific purposes does not allow the use of animal-based methods when other methods not entailing the use of animals exist, which would allow obtaining the results sought (Articles 4 “Principle of replacement, reduction and refinement” and 13 “Choice of method”). The EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) avails of the scientific opinion of the EURL ECVAM Scientific Advisory Committee (ESAC) about specific issues related to alternative methods. In 1998, based on the available evidence, ESAC concluded that for all levels of monoclonal antibody production, scientifically acceptable in vitro methods (i.e. use of hybridomas) were practicably available and that these methods were either better than, or equal to, the in vivo (ascites) production method in terms of antibody quality. Thus, the ESAC stated in 1998 that in vivo production of monoclonal antibodies by the ascites method was no longer scientifically necessary, except in rare cases. Nevertheless, the recent statistical information published by the European Commission on the use of animals for scientific purposes in the EU show an increase by 65% in the use of animals for monoclonal antibody production by the mouse ascites method between 2015 (27333 animals used) and 2017 (45024 animals used). It is unclear from the non-technical project summaries how the ascites method could be justified and as a consequence, why such projects could still be authorised in EU countries.
Ver mais
Ver menos
ISSN 1831-9424
ISBN 978-92-76-18346-4
DOI 10.2760/80554
Número de catálogo KJ-NA-30185-EN-N
ISSN 1831-9424
ISBN 978-92-76-20664-4
DOI 10.2760/695611
Número de catálogo KJ-NA-30185-EN-E
ISSN 1018-5593
ISBN 978-92-76-18347-1
DOI 10.2760/091625
Número de catálogo KJ-NA-30185-EN-C
PDF
ISSN 1831-9424 ISBN 978-92-76-18346-4 DOI 10.2760/80554 Número de catálogo KJ-NA-30185-EN-N
E-book
Tamanho: 7 474KB
ISSN 1831-9424 ISBN 978-92-76-20664-4 DOI 10.2760/695611 Número de catálogo KJ-NA-30185-EN-E
Papel
ISSN 1018-5593 ISBN 978-92-76-18347-1 DOI 10.2760/091625 Número de catálogo KJ-NA-30185-EN-C
  • Released on EU publications website:
This publication is available for download in web format (PDF) and in print-quality format (PDF/X). Para mais informações sobre como imprimir a sua própria cópia das publicações da UE, consulte a secção «Perguntas frequentes».
Publication Viewer

Visualização de documentos

Pop up window annotations